Skip to Content
Know what to ask with our GIST Doctor Discussion Guide

Penicillamine Pregnancy and Breastfeeding Warnings

Penicillamine is also known as: Cuprimine, Depen, Depen Titratabs

Penicillamine Pregnancy Warnings

Penicillamine has been assigned to pregnancy category D by the FDA. Penicillamine can cause fetal harm when administered to a pregnant woman. Penicillamine has been shown to be embryotoxic and teratogenic in rats. There are no controlled data in human pregnancy. Although normal outcomes have been reported, characteristic congenital cutis laxa and associated birth defects have been reported in infants born of mothers who received therapy with penicillamine during pregnancy. Several conflicting recommendations have appeared in the literature concerning the use of penicillamine during pregnancy. Although evidence is incomplete, maintaining the daily dose at 500 mg or less may reduce the incidence of penicillamine-induced toxicity in the newborn. The manufacturer recommends, however, that the daily dose be limited to 750 mg and, if cesarean section is planned, the dose should be limited to 250 mg/day for 6 weeks before delivery and postoperatively until wound healing is complete.

See references

Penicillamine Breastfeeding Warnings

Penicillamine is excreted into human milk. Breast-feeding is considered contraindicated by the manufacturer.

A 2000 review stated that no adverse effects in nursing infants have been reported by nursing mothers who were taking penicillamine, even though one study found lower amounts of zinc and copper in milk.

See references

References for pregnancy information

  1. "Product Information. Cuprimine (penicillamine)." Merck & Co, Inc, West Point, PA.
  2. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 7th ed." Philadelphia, PA: Lippincott Williams & Wilkins (2005):

References for breastfeeding information

  1. Briggs GG, Freeman RK, Yaffe SJ.. "Drugs in Pregnancy and Lactation. 7th ed." Philadelphia, PA: Lippincott Williams & Wilkins (2005):
  2. "Product Information. Cuprimine (penicillamine)." Merck & Co, Inc, West Point, PA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.